Muyuan Foods (SZ:002714) Jing Ji Ri Bao·2025-08-01 21:37Group 1 - The core viewpoint of the article is that Nanyang City is actively developing a biomanufacturing industry by implementing an action plan that focuses on project traction, platform construction, and element guarantee to transform research achievements into industrial applications [1][2] - The establishment of the Henan Qianmu Biopharmaceutical project, a joint investment by Qianhong Pharmaceutical and Muyuan Group, fills the gap in high-end heparin raw materials in Henan Province and integrates Nanyang's biopharmaceutical industry into the global value chain [1] - Nanyang currently has 46 biopharmaceutical enterprises above designated size, with an expected total industry chain output value of approximately 40 billion yuan in 2024 [1] Group 2 - Nanyang is enhancing its strategic laboratory construction, with the Muyuan Laboratory's "one center, one base" development model and the Zhengzhou R&D center operating in an orderly manner [2] - The first technology transfer project from Nanyang's pilot base, the "Muyuan Anliang Isolucine Project," is expected to achieve an annual output value of about 240 million yuan [2] - The city is building a technology innovation system that integrates production, education, research, and application, leveraging the advantages of key research platforms and local universities [2]